pinning.
Compound atlas
Performance

ACE-031

Also known as · ActRIIB-Fc

Myostatin trap (biologic)
Half-life
240h
approx. mean t½
Dose range
1–3 mg/kg
typical, not prescriptive
Category
Performance
primary use-case
Single-dose decay
t½ = 10d · first-order model
~40d
to clear
1× t½
50%
remaining
2× t½
25%
remaining
~4× t½
6%
remaining
0%25%50%75%100%0m10d20d30d40d50dt½

How a single dose clears, assuming first-order elimination. The half-life is the biggest driver of how often you dose — start a cycle to see your own cumulative concentration curve.

— Overview

A myostatin-pathway inhibitor (ActRIIB decoy) trialed for muscular dystrophy; trials stopped over vascular safety signals.

— Mechanism of action

Acts as a soluble receptor 'trap' binding myostatin and related ligands, releasing the brake on muscle growth.

— Typical protocol

Investigational only; dosing from halted trials.

— Storage

Refrigerated; protect from light.

Disclaimer

This page summarizes publicly available information. None of it constitutes medical advice, prescription, or recommendation to acquire, possess, or use any compound. Many peptides described are research chemicals not approved for human use in the EU. Consult a licensed physician.

Tool
Reconstitute ACE-031
Vendor reviews
See sources
— Related compounds
Performance

LGD-4033

A selective androgen receptor modulator studied for lean-mass gains with fewer androgenic side effects than steroids. Not approved; banned in sport (WADA).

Performance

RAD-140

A potent SARM studied for strength and lean mass. Not approved; banned in sport. Notable suppression and liver-marker effects reported.

Performance

Ostarine

One of the most-studied SARMs, investigated for muscle-wasting conditions. Not approved; banned in sport.